nodes	percent_of_prediction	percent_of_DWPC	metapath
Ergotamine—CYP1A2—Methimazole—Graves' disease	0.597	0.656	CbGbCtD
Ergotamine—CYP3A4—Methimazole—Graves' disease	0.313	0.344	CbGbCtD
Ergotamine—Vertigo—Methimazole—Graves' disease	0.00643	0.101	CcSEcCtD
Ergotamine—Myalgia—Methimazole—Graves' disease	0.00609	0.0957	CcSEcCtD
Ergotamine—Vertigo—Propylthiouracil—Graves' disease	0.00546	0.0859	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Methimazole—Graves' disease	0.00532	0.0836	CcSEcCtD
Ergotamine—Paraesthesia—Methimazole—Graves' disease	0.00524	0.0824	CcSEcCtD
Ergotamine—Myalgia—Propylthiouracil—Graves' disease	0.00518	0.0814	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Propylthiouracil—Graves' disease	0.00452	0.0711	CcSEcCtD
Ergotamine—Paraesthesia—Propylthiouracil—Graves' disease	0.00446	0.0701	CcSEcCtD
Ergotamine—Pruritus—Methimazole—Graves' disease	0.00413	0.0649	CcSEcCtD
Ergotamine—Vomiting—Methimazole—Graves' disease	0.00371	0.0583	CcSEcCtD
Ergotamine—Pruritus—Propylthiouracil—Graves' disease	0.00351	0.0552	CcSEcCtD
Ergotamine—Nausea—Methimazole—Graves' disease	0.00347	0.0545	CcSEcCtD
Ergotamine—Vomiting—Propylthiouracil—Graves' disease	0.00316	0.0496	CcSEcCtD
Ergotamine—Nausea—Propylthiouracil—Graves' disease	0.00295	0.0463	CcSEcCtD
Ergotamine—HTR1F—GPCRs, Class A Rhodopsin-like—GPR174—Graves' disease	0.00144	0.0551	CbGpPWpGaD
Ergotamine—HTR1E—GPCRs, Class A Rhodopsin-like—GPR174—Graves' disease	0.00136	0.052	CbGpPWpGaD
Ergotamine—HTR1D—GPCRs, Class A Rhodopsin-like—GPR174—Graves' disease	0.000924	0.0352	CbGpPWpGaD
Ergotamine—HTR1B—GPCRs, Class A Rhodopsin-like—GPR174—Graves' disease	0.000905	0.0345	CbGpPWpGaD
Ergotamine—HTR2B—GPCRs, Class A Rhodopsin-like—GPR174—Graves' disease	0.00085	0.0324	CbGpPWpGaD
Ergotamine—ADRA1D—GPCRs, Class A Rhodopsin-like—GPR174—Graves' disease	0.000791	0.0302	CbGpPWpGaD
Ergotamine—ADRA2B—GPCRs, Class A Rhodopsin-like—GPR174—Graves' disease	0.000714	0.0272	CbGpPWpGaD
Ergotamine—HTR1A—GPCRs, Class A Rhodopsin-like—GPR174—Graves' disease	0.000689	0.0263	CbGpPWpGaD
Ergotamine—HTR2C—GPCRs, Class A Rhodopsin-like—GPR174—Graves' disease	0.000686	0.0261	CbGpPWpGaD
Ergotamine—ADRA1B—GPCRs, Class A Rhodopsin-like—GPR174—Graves' disease	0.000656	0.025	CbGpPWpGaD
Ergotamine—DRD2—GPCRs, Class A Rhodopsin-like—GPR174—Graves' disease	0.000605	0.0231	CbGpPWpGaD
Ergotamine—HTR2A—GPCRs, Class A Rhodopsin-like—GPR174—Graves' disease	0.000595	0.0227	CbGpPWpGaD
Ergotamine—ADRA1A—GPCRs, Class A Rhodopsin-like—GPR174—Graves' disease	0.000583	0.0222	CbGpPWpGaD
Ergotamine—ADRA2A—GPCRs, Class A Rhodopsin-like—GPR174—Graves' disease	0.000542	0.0207	CbGpPWpGaD
Ergotamine—SLC6A2—Monoamine Transport—IL1B—Graves' disease	0.000279	0.0106	CbGpPWpGaD
Ergotamine—HTR1F—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000263	0.01	CbGpPWpGaD
Ergotamine—HTR1E—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000248	0.00946	CbGpPWpGaD
Ergotamine—HTR1F—G alpha (i) signalling events—CXCL10—Graves' disease	0.000214	0.00815	CbGpPWpGaD
Ergotamine—SLC6A2—Monoamine Transport—TNF—Graves' disease	0.000203	0.00772	CbGpPWpGaD
Ergotamine—HTR1E—G alpha (i) signalling events—CXCL10—Graves' disease	0.000202	0.00769	CbGpPWpGaD
Ergotamine—HTR1F—GPCR ligand binding—TSHR—Graves' disease	0.0002	0.00764	CbGpPWpGaD
Ergotamine—HTR1E—GPCR ligand binding—TSHR—Graves' disease	0.000189	0.00721	CbGpPWpGaD
Ergotamine—HTR1F—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.00017	0.00648	CbGpPWpGaD
Ergotamine—HTR1D—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000168	0.00642	CbGpPWpGaD
Ergotamine—HTR1B—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000165	0.00628	CbGpPWpGaD
Ergotamine—HTR1E—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.00016	0.00612	CbGpPWpGaD
Ergotamine—HTR2B—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000155	0.0059	CbGpPWpGaD
Ergotamine—ABCB1—Allograft Rejection—HLA-E—Graves' disease	0.000152	0.00579	CbGpPWpGaD
Ergotamine—ABCB1—Allograft Rejection—CD40—Graves' disease	0.000148	0.00566	CbGpPWpGaD
Ergotamine—ABCB1—Allograft Rejection—CTLA4—Graves' disease	0.000146	0.00558	CbGpPWpGaD
Ergotamine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000144	0.00549	CbGpPWpGaD
Ergotamine—HTR1D—G alpha (i) signalling events—CXCL10—Graves' disease	0.000137	0.00521	CbGpPWpGaD
Ergotamine—SLC6A2—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.000135	0.00515	CbGpPWpGaD
Ergotamine—HTR1B—G alpha (i) signalling events—CXCL10—Graves' disease	0.000134	0.00511	CbGpPWpGaD
Ergotamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.00013	0.00496	CbGpPWpGaD
Ergotamine—HTR1F—GPCR ligand binding—CXCL10—Graves' disease	0.000129	0.00494	CbGpPWpGaD
Ergotamine—HTR1D—GPCR ligand binding—TSHR—Graves' disease	0.000128	0.00489	CbGpPWpGaD
Ergotamine—HTR1A—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000126	0.00479	CbGpPWpGaD
Ergotamine—HTR1B—GPCR ligand binding—TSHR—Graves' disease	0.000125	0.00478	CbGpPWpGaD
Ergotamine—HTR2C—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000125	0.00476	CbGpPWpGaD
Ergotamine—HTR1E—GPCR ligand binding—CXCL10—Graves' disease	0.000122	0.00466	CbGpPWpGaD
Ergotamine—ABCB1—Allograft Rejection—HLA-DQB1—Graves' disease	0.00012	0.00459	CbGpPWpGaD
Ergotamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.00012	0.00456	CbGpPWpGaD
Ergotamine—HTR2B—GPCR ligand binding—TSHR—Graves' disease	0.000118	0.00449	CbGpPWpGaD
Ergotamine—HTR1F—GPCR downstream signaling—TSHR—Graves' disease	0.000113	0.00432	CbGpPWpGaD
Ergotamine—DRD2—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.00011	0.0042	CbGpPWpGaD
Ergotamine—ADRA1D—GPCR ligand binding—TSHR—Graves' disease	0.00011	0.00418	CbGpPWpGaD
Ergotamine—HTR1D—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000109	0.00415	CbGpPWpGaD
Ergotamine—HTR2A—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000108	0.00413	CbGpPWpGaD
Ergotamine—ABCB1—Allograft Rejection—HLA-B—Graves' disease	0.000108	0.00412	CbGpPWpGaD
Ergotamine—HTR1E—GPCR downstream signaling—TSHR—Graves' disease	0.000107	0.00407	CbGpPWpGaD
Ergotamine—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000106	0.00406	CbGpPWpGaD
Ergotamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000106	0.00405	CbGpPWpGaD
Ergotamine—ABCB1—Allograft Rejection—FASLG—Graves' disease	0.000106	0.00403	CbGpPWpGaD
Ergotamine—ADRA2B—G alpha (i) signalling events—CXCL10—Graves' disease	0.000106	0.00403	CbGpPWpGaD
Ergotamine—HTR1F—Signaling by GPCR—TSHR—Graves' disease	0.000103	0.00392	CbGpPWpGaD
Ergotamine—HTR1A—G alpha (i) signalling events—CXCL10—Graves' disease	0.000102	0.00389	CbGpPWpGaD
Ergotamine—ABCB1—Allograft Rejection—FAS—Graves' disease	0.000102	0.00389	CbGpPWpGaD
Ergotamine—ABCB1—Allograft Rejection—IL2RA—Graves' disease	0.000101	0.00386	CbGpPWpGaD
Ergotamine—ABCB1—Allograft Rejection—HLA-A—Graves' disease	0.0001	0.00382	CbGpPWpGaD
Ergotamine—HTR2B—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.0001	0.00381	CbGpPWpGaD
Ergotamine—ADRA2B—GPCR ligand binding—TSHR—Graves' disease	9.9e-05	0.00378	CbGpPWpGaD
Ergotamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	9.87e-05	0.00376	CbGpPWpGaD
Ergotamine—HTR1E—Signaling by GPCR—TSHR—Graves' disease	9.7e-05	0.0037	CbGpPWpGaD
Ergotamine—HTR1A—GPCR ligand binding—TSHR—Graves' disease	9.56e-05	0.00364	CbGpPWpGaD
Ergotamine—HTR2C—GPCR ligand binding—TSHR—Graves' disease	9.51e-05	0.00363	CbGpPWpGaD
Ergotamine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	9.31e-05	0.00355	CbGpPWpGaD
Ergotamine—ABCB1—Allograft Rejection—HLA-DRB1—Graves' disease	9.16e-05	0.00349	CbGpPWpGaD
Ergotamine—ADRA1B—GPCR ligand binding—TSHR—Graves' disease	9.1e-05	0.00347	CbGpPWpGaD
Ergotamine—DRD2—G alpha (i) signalling events—CXCL10—Graves' disease	8.96e-05	0.00341	CbGpPWpGaD
Ergotamine—ADRA2B—Platelet activation, signaling and aggregation—IL2RA—Graves' disease	8.48e-05	0.00323	CbGpPWpGaD
Ergotamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	8.4e-05	0.0032	CbGpPWpGaD
Ergotamine—DRD2—GPCR ligand binding—TSHR—Graves' disease	8.39e-05	0.0032	CbGpPWpGaD
Ergotamine—HTR1D—GPCR ligand binding—CXCL10—Graves' disease	8.28e-05	0.00316	CbGpPWpGaD
Ergotamine—HTR2A—GPCR ligand binding—TSHR—Graves' disease	8.26e-05	0.00315	CbGpPWpGaD
Ergotamine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—Graves' disease	8.23e-05	0.00314	CbGpPWpGaD
Ergotamine—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	8.11e-05	0.00309	CbGpPWpGaD
Ergotamine—HTR1B—GPCR ligand binding—CXCL10—Graves' disease	8.11e-05	0.00309	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR ligand binding—TSHR—Graves' disease	8.09e-05	0.00308	CbGpPWpGaD
Ergotamine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	8.07e-05	0.00308	CbGpPWpGaD
Ergotamine—ADRA2A—G alpha (i) signalling events—CXCL10—Graves' disease	8.02e-05	0.00306	CbGpPWpGaD
Ergotamine—DRD2—Circadian rythm related genes—FAS—Graves' disease	7.8e-05	0.00297	CbGpPWpGaD
Ergotamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	7.72e-05	0.00294	CbGpPWpGaD
Ergotamine—HTR2B—GPCR ligand binding—CXCL10—Graves' disease	7.62e-05	0.0029	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR ligand binding—TSHR—Graves' disease	7.51e-05	0.00286	CbGpPWpGaD
Ergotamine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—Graves' disease	7.34e-05	0.0028	CbGpPWpGaD
Ergotamine—HTR1F—GPCR downstream signaling—CXCL10—Graves' disease	7.32e-05	0.00279	CbGpPWpGaD
Ergotamine—HTR1D—GPCR downstream signaling—TSHR—Graves' disease	7.24e-05	0.00276	CbGpPWpGaD
Ergotamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	7.12e-05	0.00272	CbGpPWpGaD
Ergotamine—HTR1B—GPCR downstream signaling—TSHR—Graves' disease	7.09e-05	0.0027	CbGpPWpGaD
Ergotamine—ADRA1D—GPCR ligand binding—CXCL10—Graves' disease	7.09e-05	0.0027	CbGpPWpGaD
Ergotamine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	7.01e-05	0.00267	CbGpPWpGaD
Ergotamine—HTR1E—GPCR downstream signaling—CXCL10—Graves' disease	6.9e-05	0.00263	CbGpPWpGaD
Ergotamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	6.86e-05	0.00262	CbGpPWpGaD
Ergotamine—ABCB1—Allograft Rejection—IFNG—Graves' disease	6.69e-05	0.00255	CbGpPWpGaD
Ergotamine—HTR2B—GPCR downstream signaling—TSHR—Graves' disease	6.66e-05	0.00254	CbGpPWpGaD
Ergotamine—HTR1F—Signaling by GPCR—CXCL10—Graves' disease	6.64e-05	0.00253	CbGpPWpGaD
Ergotamine—HTR1D—Signaling by GPCR—TSHR—Graves' disease	6.58e-05	0.00251	CbGpPWpGaD
Ergotamine—HTR1B—Signaling by GPCR—TSHR—Graves' disease	6.44e-05	0.00246	CbGpPWpGaD
Ergotamine—ADRA2A—Platelet activation, signaling and aggregation—IL2RA—Graves' disease	6.44e-05	0.00245	CbGpPWpGaD
Ergotamine—ADRA2B—GPCR ligand binding—CXCL10—Graves' disease	6.4e-05	0.00244	CbGpPWpGaD
Ergotamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	6.37e-05	0.00243	CbGpPWpGaD
Ergotamine—HTR1A—SIDS Susceptibility Pathways—IL1B—Graves' disease	6.37e-05	0.00243	CbGpPWpGaD
Ergotamine—HTR1E—Signaling by GPCR—CXCL10—Graves' disease	6.27e-05	0.00239	CbGpPWpGaD
Ergotamine—ADRA1D—GPCR downstream signaling—TSHR—Graves' disease	6.2e-05	0.00236	CbGpPWpGaD
Ergotamine—HTR1A—GPCR ligand binding—CXCL10—Graves' disease	6.18e-05	0.00235	CbGpPWpGaD
Ergotamine—HTR2C—GPCR ligand binding—CXCL10—Graves' disease	6.14e-05	0.00234	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—TSHR—Graves' disease	6.07e-05	0.00232	CbGpPWpGaD
Ergotamine—HTR2B—Signaling by GPCR—TSHR—Graves' disease	6.05e-05	0.00231	CbGpPWpGaD
Ergotamine—ABCB1—Allograft Rejection—IL1B—Graves' disease	5.96e-05	0.00227	CbGpPWpGaD
Ergotamine—ABCB1—Transmembrane transport of small molecules—GABRA3—Graves' disease	5.95e-05	0.00227	CbGpPWpGaD
Ergotamine—ADRA1B—GPCR ligand binding—CXCL10—Graves' disease	5.88e-05	0.00224	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—TSHR—Graves' disease	5.73e-05	0.00218	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling by GPCR—TSHR—Graves' disease	5.63e-05	0.00215	CbGpPWpGaD
Ergotamine—ADRA2B—GPCR downstream signaling—TSHR—Graves' disease	5.6e-05	0.00213	CbGpPWpGaD
Ergotamine—HTR1F—GPCR downstream signaling—IL2RA—Graves' disease	5.59e-05	0.00213	CbGpPWpGaD
Ergotamine—HTR2A—SIDS Susceptibility Pathways—IL1B—Graves' disease	5.5e-05	0.0021	CbGpPWpGaD
Ergotamine—DRD2—GPCR ligand binding—CXCL10—Graves' disease	5.42e-05	0.00207	CbGpPWpGaD
Ergotamine—HTR1A—GPCR downstream signaling—TSHR—Graves' disease	5.4e-05	0.00206	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism of lipids and lipoproteins—GC—Graves' disease	5.38e-05	0.00205	CbGpPWpGaD
Ergotamine—HTR2C—GPCR downstream signaling—TSHR—Graves' disease	5.37e-05	0.00205	CbGpPWpGaD
Ergotamine—HTR2A—GPCR ligand binding—CXCL10—Graves' disease	5.34e-05	0.00203	CbGpPWpGaD
Ergotamine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—Graves' disease	5.33e-05	0.00203	CbGpPWpGaD
Ergotamine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—Graves' disease	5.33e-05	0.00203	CbGpPWpGaD
Ergotamine—HTR1E—GPCR downstream signaling—IL2RA—Graves' disease	5.28e-05	0.00201	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR ligand binding—CXCL10—Graves' disease	5.22e-05	0.00199	CbGpPWpGaD
Ergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	5.22e-05	0.00199	CbGpPWpGaD
Ergotamine—ADRA1B—GPCR downstream signaling—TSHR—Graves' disease	5.14e-05	0.00196	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—TSHR—Graves' disease	5.08e-05	0.00194	CbGpPWpGaD
Ergotamine—HTR1F—Signaling by GPCR—IL2RA—Graves' disease	5.08e-05	0.00194	CbGpPWpGaD
Ergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	5.03e-05	0.00192	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—TSHR—Graves' disease	4.91e-05	0.00187	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—TSHR—Graves' disease	4.88e-05	0.00186	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR ligand binding—CXCL10—Graves' disease	4.85e-05	0.00185	CbGpPWpGaD
Ergotamine—HTR1E—Signaling by GPCR—IL2RA—Graves' disease	4.79e-05	0.00183	CbGpPWpGaD
Ergotamine—DRD2—GPCR downstream signaling—TSHR—Graves' disease	4.74e-05	0.00181	CbGpPWpGaD
Ergotamine—HTR1D—GPCR downstream signaling—CXCL10—Graves' disease	4.68e-05	0.00178	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—TSHR—Graves' disease	4.67e-05	0.00178	CbGpPWpGaD
Ergotamine—HTR2A—GPCR downstream signaling—TSHR—Graves' disease	4.67e-05	0.00178	CbGpPWpGaD
Ergotamine—HTR1A—SIDS Susceptibility Pathways—TNF—Graves' disease	4.62e-05	0.00176	CbGpPWpGaD
Ergotamine—HTR1B—GPCR downstream signaling—CXCL10—Graves' disease	4.58e-05	0.00175	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR downstream signaling—TSHR—Graves' disease	4.57e-05	0.00174	CbGpPWpGaD
Ergotamine—ADRA2B—Hemostasis—IL2RA—Graves' disease	4.37e-05	0.00167	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—GC—Graves' disease	4.34e-05	0.00165	CbGpPWpGaD
Ergotamine—ABCB1—Allograft Rejection—TNF—Graves' disease	4.33e-05	0.00165	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—TSHR—Graves' disease	4.31e-05	0.00164	CbGpPWpGaD
Ergotamine—HTR2B—GPCR downstream signaling—CXCL10—Graves' disease	4.3e-05	0.00164	CbGpPWpGaD
Ergotamine—HTR1D—Signaling by GPCR—CXCL10—Graves' disease	4.25e-05	0.00162	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—TSHR—Graves' disease	4.25e-05	0.00162	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—TSHR—Graves' disease	4.24e-05	0.00162	CbGpPWpGaD
Ergotamine—HTR1B—Signaling by GPCR—CXCL10—Graves' disease	4.16e-05	0.00159	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—TSHR—Graves' disease	4.15e-05	0.00158	CbGpPWpGaD
Ergotamine—ADRA1D—GPCR downstream signaling—CXCL10—Graves' disease	4e-05	0.00153	CbGpPWpGaD
Ergotamine—HTR2A—SIDS Susceptibility Pathways—TNF—Graves' disease	3.99e-05	0.00152	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—CXCL10—Graves' disease	3.93e-05	0.0015	CbGpPWpGaD
Ergotamine—HTR2B—Signaling by GPCR—CXCL10—Graves' disease	3.91e-05	0.00149	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—TSHR—Graves' disease	3.88e-05	0.00148	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—TSHR—Graves' disease	3.86e-05	0.00147	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—TSHR—Graves' disease	3.8e-05	0.00145	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—CXCL10—Graves' disease	3.7e-05	0.00141	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling by GPCR—CXCL10—Graves' disease	3.64e-05	0.00139	CbGpPWpGaD
Ergotamine—ADRA2B—GPCR downstream signaling—CXCL10—Graves' disease	3.62e-05	0.00138	CbGpPWpGaD
Ergotamine—HTR1D—GPCR downstream signaling—IL2RA—Graves' disease	3.58e-05	0.00136	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—TSHR—Graves' disease	3.57e-05	0.00136	CbGpPWpGaD
Ergotamine—HTR1B—GPCR downstream signaling—IL2RA—Graves' disease	3.5e-05	0.00134	CbGpPWpGaD
Ergotamine—HTR1A—GPCR downstream signaling—CXCL10—Graves' disease	3.49e-05	0.00133	CbGpPWpGaD
Ergotamine—HTR2C—GPCR downstream signaling—CXCL10—Graves' disease	3.47e-05	0.00132	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—TSHR—Graves' disease	3.32e-05	0.00127	CbGpPWpGaD
Ergotamine—ADRA1B—GPCR downstream signaling—CXCL10—Graves' disease	3.32e-05	0.00127	CbGpPWpGaD
Ergotamine—ADRA2A—Hemostasis—IL2RA—Graves' disease	3.32e-05	0.00126	CbGpPWpGaD
Ergotamine—HTR2B—GPCR downstream signaling—IL2RA—Graves' disease	3.29e-05	0.00125	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—B3GNT2—Graves' disease	3.29e-05	0.00125	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—CXCL10—Graves' disease	3.28e-05	0.00125	CbGpPWpGaD
Ergotamine—HTR1D—Signaling by GPCR—IL2RA—Graves' disease	3.25e-05	0.00124	CbGpPWpGaD
Ergotamine—HTR1B—Signaling by GPCR—IL2RA—Graves' disease	3.18e-05	0.00121	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—CXCL10—Graves' disease	3.17e-05	0.00121	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—CXCL10—Graves' disease	3.15e-05	0.0012	CbGpPWpGaD
Ergotamine—DRD2—GPCR downstream signaling—CXCL10—Graves' disease	3.06e-05	0.00117	CbGpPWpGaD
Ergotamine—ADRA1D—GPCR downstream signaling—IL2RA—Graves' disease	3.06e-05	0.00117	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—CXCL10—Graves' disease	3.02e-05	0.00115	CbGpPWpGaD
Ergotamine—HTR2A—GPCR downstream signaling—CXCL10—Graves' disease	3.02e-05	0.00115	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—TSHR—Graves' disease	3e-05	0.00114	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—IL2RA—Graves' disease	3e-05	0.00114	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—GC—Graves' disease	3e-05	0.00114	CbGpPWpGaD
Ergotamine—HTR2B—Signaling by GPCR—IL2RA—Graves' disease	2.99e-05	0.00114	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR downstream signaling—CXCL10—Graves' disease	2.95e-05	0.00113	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—TSHR—Graves' disease	2.9e-05	0.0011	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—TSHR—Graves' disease	2.88e-05	0.0011	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—IL2RA—Graves' disease	2.83e-05	0.00108	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—CXCL10—Graves' disease	2.78e-05	0.00106	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling by GPCR—IL2RA—Graves' disease	2.78e-05	0.00106	CbGpPWpGaD
Ergotamine—ADRA2B—GPCR downstream signaling—IL2RA—Graves' disease	2.76e-05	0.00105	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—TSHR—Graves' disease	2.76e-05	0.00105	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—CXCL10—Graves' disease	2.74e-05	0.00105	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—CXCL10—Graves' disease	2.74e-05	0.00104	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—CXCL10—Graves' disease	2.68e-05	0.00102	CbGpPWpGaD
Ergotamine—HTR1A—GPCR downstream signaling—IL2RA—Graves' disease	2.67e-05	0.00102	CbGpPWpGaD
Ergotamine—HTR2C—GPCR downstream signaling—IL2RA—Graves' disease	2.65e-05	0.00101	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—TSHR—Graves' disease	2.54e-05	0.00097	CbGpPWpGaD
Ergotamine—ADRA1B—GPCR downstream signaling—IL2RA—Graves' disease	2.54e-05	0.000969	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—CXCL10—Graves' disease	2.51e-05	0.000957	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—IL2RA—Graves' disease	2.51e-05	0.000957	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—TSHR—Graves' disease	2.5e-05	0.000954	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—CXCL10—Graves' disease	2.49e-05	0.00095	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—CXCL10—Graves' disease	2.46e-05	0.000937	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—TSHR—Graves' disease	2.45e-05	0.000935	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—IL2RA—Graves' disease	2.42e-05	0.000924	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—IL2RA—Graves' disease	2.41e-05	0.000919	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—GC—Graves' disease	2.39e-05	0.000913	CbGpPWpGaD
Ergotamine—DRD2—GPCR downstream signaling—IL2RA—Graves' disease	2.34e-05	0.000893	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—CXCL10—Graves' disease	2.31e-05	0.00088	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—IL2RA—Graves' disease	2.31e-05	0.00088	CbGpPWpGaD
Ergotamine—HTR2A—GPCR downstream signaling—IL2RA—Graves' disease	2.3e-05	0.000879	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—TSHR—Graves' disease	2.28e-05	0.000868	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—B3GNT2—Graves' disease	2.27e-05	0.000867	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR downstream signaling—IL2RA—Graves' disease	2.26e-05	0.00086	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—CXCL10—Graves' disease	2.15e-05	0.000819	CbGpPWpGaD
Ergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	2.14e-05	0.000814	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—IL2RA—Graves' disease	2.13e-05	0.000811	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—IL2RA—Graves' disease	2.1e-05	0.000799	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—IL2RA—Graves' disease	2.09e-05	0.000798	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—IL2RA—Graves' disease	2.05e-05	0.000781	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—CXCL10—Graves' disease	1.94e-05	0.00074	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—IL2RA—Graves' disease	1.92e-05	0.000732	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—IL2RA—Graves' disease	1.9e-05	0.000726	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—IL2RA—Graves' disease	1.88e-05	0.000716	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—CXCL10—Graves' disease	1.87e-05	0.000714	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—CXCL10—Graves' disease	1.86e-05	0.00071	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—GC—Graves' disease	1.85e-05	0.000705	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—B3GNT2—Graves' disease	1.81e-05	0.000692	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CXCL10—Graves' disease	1.78e-05	0.00068	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—IL2RA—Graves' disease	1.76e-05	0.000673	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CXCL10—Graves' disease	1.64e-05	0.000627	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—IL2RA—Graves' disease	1.64e-05	0.000626	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CXCL10—Graves' disease	1.62e-05	0.000617	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CXCL10—Graves' disease	1.58e-05	0.000604	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—IL2RA—Graves' disease	1.48e-05	0.000565	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CXCL10—Graves' disease	1.47e-05	0.000561	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—IL2RA—Graves' disease	1.43e-05	0.000546	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—IL2RA—Graves' disease	1.42e-05	0.000543	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—B3GNT2—Graves' disease	1.4e-05	0.000534	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—IL2RA—Graves' disease	1.36e-05	0.00052	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—IL2RA—Graves' disease	1.26e-05	0.000479	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—IL2RA—Graves' disease	1.24e-05	0.000471	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—IL2RA—Graves' disease	1.21e-05	0.000462	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—IL2RA—Graves' disease	1.12e-05	0.000429	CbGpPWpGaD
